Welcome to #TenTootNephJC
✳️10 toots to catch you up on the latest from #NephJC ✳️

At the end of May, NephJC discussed interim results📊from PROTECT trial on efficacy & safety of Sparsentan in IgAN.

New light✨on the horizon for IgAN yet?

Check out this flying summary in case you've missed the chat!
http://www.nephjc.com/news/sparsentan-protect

Welcome to #TenTootNephJC

✳️10 toot #NephJC catch-up ✳️

🌟Let’s recap the RITAZAREM trial - a rematch between Rituximab & Azathioprine as the maintenance agent of choice in relapsed ANCA-associated vasculitis (AAV).

🌟Have we witnessed the ultimate triumph of Rituximab?

10/10
Final thoughts

✳️ What we really want to see is the anticoagulation versus no anticoagulation RCTs!

➡️ Up next on March 28/29 - MMF Monotherapy in IgA Nephropathy: an RCT https://pubmed.ncbi.nlm.nih.gov/36745456/

Catch the summaries here:
http://nephjc.com

#TenTootNephJC brought to you by @willows & @jmteakell
#NephJC

Many nephrologists make decisions about which anticoagulant (if any) to recommend for atrial fibrillation in patients on haemodialysis on a weekly basis.

And we finally have more randomised data!

Enjoy a rapid catch-up with this #TenTootNephJC

http://www.nephjc.com/news/af-in-esrd

Welcome to #TenTootNephJC

✳️10 toots to catch-up on the last #NephJC ✳️

We all have our “go to” diuretics that are better, faster, stronger…but are they?
What evidence is there that one diuretic (in a class) is superior to another (same class) for CV outcomes?
It’s a 2-fer TenToots.
http://www.nephjc.com/news/2023/1/28/the-diuretic-wars-continue

Let’s go…